ABCL Stock: Price, Earnings History and SEC Filings
AbCellera Biologics Inc. (ABCL) last traded at $12.27, down 6.19% on the latest session and down 15.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.18 against an analyst estimate of $-0.17, a miss of 5.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ABCL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.18 | $-0.17 | -5.88% |
| Mar 2026 | May 11, 2026 | $-0.14 | $-0.22 | +36.36% |
| Dec 2025 | Feb 24, 2026 | $-0.03 | $-0.18 | +83.33% |
| Sep 2025 | Nov 6, 2025 | $-0.19 | $-0.17 | -11.76% |
ABCL beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How ABCL reacts to earnings
Across its last 8 earnings releases, ABCL moved 6.2% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +10.30% |
| 2026-05-11 | After close | -5.71% |
| 2026-02-24 | After close | -0.93% |
| 2025-11-06 | After close | -13.69% |
| 2025-08-07 | After close | +0.24% |
| 2025-05-08 | After close | +1.00% |
| 2025-02-27 | After close | -11.47% |
| 2024-11-04 | After close | -5.88% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ABCL financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $75M | -$146M | -$174M | -194.9% | $-0.49 |
| 2024 | $29M | -$163M | -$187M | -564.8% | $-0.55 |
| 2023 | $38M | -$146M | -$121M | -385.0% | $-0.51 |
| 2022 | $485M | $159M | $207M | 32.7% | $0.50 |
| 2021 | $375M | $153M | $186M | 40.9% | $0.48 |
| 2020 | $233M | $119M | $13M | 51.0% | $0.45 |
| 2019 | $12M | -$2M | -$1M | -19.0% | $-0.01 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ABCL
- 8-K · Aug 13, 2026Material agreement, Other events, Financial statements and exhibits
- 424B5 · Aug 13, 2026
- 424B5 · Aug 11, 2026
- 8-K · Aug 10, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 7, 2026Other events, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jul 29, 2026Other events, Financial statements and exhibits
- 8-K · Jul 6, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jun 17, 2026Other events, Financial statements and exhibits
Insider filing activity
ABCL insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ABCL news
- AbCellera to Present at Upcoming Investor Conferences in November 2026Oct 22, 2026 · finance.yahoo.com
About AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in British Columbia Canada. Its fiscal year ends in December.